Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia

Status: open

17-019 - A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia

Treatment for Preeclampsia

Contact Us Or call 251-415-1598

Description

This study evaluates the use of Digoxin immune fab in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.

Sponsors

This trial is sponsored by Velo Bio, LLC.

Providers Associated With This Trial

Sub Investigators

    This link will open in a new tab or window.